These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 33156982)

  • 21. The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial.
    Han MK; Criner GJ; Dransfield MT; Halpin DMG; Jones CE; Kilbride S; Lange P; Lettis S; Lipson DA; Lomas DA; Martin N; Wise RA; Singh D; Martinez FJ
    Am J Respir Crit Care Med; 2020 Nov; 202(9):1237-1243. PubMed ID: 32584168
    [No Abstract]   [Full Text] [Related]  

  • 22. Mortality Risk and Serious Cardiopulmonary Events in Moderate-to-Severe COPD: Post Hoc Analysis of the IMPACT Trial.
    Wells JM; Criner GJ; Halpin DMG; Han MK; Jain R; Lange P; Lipson DA; Martinez FJ; Midwinter D; Singh D; Wise RA
    Chronic Obstr Pulm Dis; 2023 Jan; 10(1):33-45. PubMed ID: 36516330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical Trials.
    Hanania NA; Caveney S; Soule T; Tombs L; Lettis S; Crim C; Mannino DM; Patel H; Boucot IH
    Int J Chron Obstruct Pulmon Dis; 2021; 16():1925-1938. PubMed ID: 34194225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial.
    Pascoe S; Barnes N; Brusselle G; Compton C; Criner GJ; Dransfield MT; Halpin DMG; Han MK; Hartley B; Lange P; Lettis S; Lipson DA; Lomas DA; Martinez FJ; Papi A; Roche N; van der Valk RJP; Wise R; Singh D
    Lancet Respir Med; 2019 Sep; 7(9):745-756. PubMed ID: 31281061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Following a COPD Exacerbation.
    Mannino D; Bogart M; Germain G; Huang SP; Ismaila AS; Laliberté F; Jung Y; MacKnight SD; Stiegler MA; Duh MS
    Int J Chron Obstruct Pulmon Dis; 2022; 17():491-504. PubMed ID: 35281476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 24-Hour Serial Spirometric Assessment of Once-Daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in Patients with COPD: Analysis of the FULFIL Study.
    Lipson DA; Birk R; Brealey N; Zhu CQ
    Adv Ther; 2020 Dec; 37(12):4894-4909. PubMed ID: 33011864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI).
    McCormack M; Paczkowski R; Gronroos NN; Noorduyn SG; Lee L; Veeranki P; Johnson MG; Igboekwe E; Kahle-Wrobleski K; Panettieri R
    Adv Ther; 2024 Mar; 41(3):1245-1261. PubMed ID: 38310193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study.
    Ismaila AS; Rothnie KJ; Wood RP; Banks VL; Camidge LJ; Czira A; Compton C; Sharma R; Millard SN; Massey O; Halpin DMG
    Respir Res; 2023 Sep; 24(1):229. PubMed ID: 37749551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD.
    Bansal S; Anderson M; Anzueto A; Brown N; Compton C; Corbridge TC; Erb D; Harvey C; Kaisermann MC; Kaye M; Lipson DA; Martin N; Zhu CQ; Papi A
    NPJ Prim Care Respir Med; 2021 May; 31(1):29. PubMed ID: 34035312
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life.
    Tabberer M; Lomas DA; Birk R; Brealey N; Zhu CQ; Pascoe S; Locantore N; Lipson DA
    Adv Ther; 2018 Jan; 35(1):56-71. PubMed ID: 29313286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterol.
    Sethi S; Palli SR; Bengtson LGS; Buysman EK; Clark B; Sargent A; Shaikh A; Ferguson GT
    J Manag Care Spec Pharm; 2023 Jul; 29(7):791-806. PubMed ID: 37133429
    [No Abstract]   [Full Text] [Related]  

  • 32. Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.
    Lipson DA; Crim C; Criner GJ; Day NC; Dransfield MT; Halpin DMG; Han MK; Jones CE; Kilbride S; Lange P; Lomas DA; Lettis S; Manchester P; Martin N; Midwinter D; Morris A; Pascoe SJ; Singh D; Wise RA; Martinez FJ
    Am J Respir Crit Care Med; 2020 Jun; 201(12):1508-1516. PubMed ID: 32162970
    [No Abstract]   [Full Text] [Related]  

  • 33. The effect of exacerbation history on outcomes in the IMPACT trial.
    Halpin DMG; Dransfield MT; Han MK; Jones CE; Kilbride S; Lange P; Lipson DA; Lomas DA; Martinez FJ; Pascoe S; Singh D; Wise R; Criner GJ
    Eur Respir J; 2020 May; 55(5):. PubMed ID: 32299860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcomes Following Initiation of Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol versus Multiple-Inhaler Triple Therapy Among Medicare Advantage with Part D Beneficiaries and Those Commercially Enrolled for Health Care Insurance in the United States.
    Bogart M; Bengtson LGS; Johnson MG; Bunner SH; Gronroos NN; DiRocco KK
    Int J Chron Obstruct Pulmon Dis; 2024; 19():97-110. PubMed ID: 38226396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. COPD exacerbation costs in the IMPACT study: a within-trial analysis.
    Bogart MR; Hopson SD; Shih HC; Stanford RH; Coutinho AD
    Am J Manag Care; 2020 May; 26(5):e150-e154. PubMed ID: 32436683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis of fluticasone furoate/umeclidinium bromide/vilanterol and umeclidinium bromide/vilanterol in the management of moderate and severe COPD in China.
    Zhou Y; Duan S; Zhang L; Peng F
    Respir Med; 2024 May; 226():107632. PubMed ID: 38621548
    [TBL] [Abstract][Full Text] [Related]  

  • 37. COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA.
    Hanania NA; Bunner SH; Bengtson LGS; Ismaila AS; Bogart M
    Int J Chron Obstruct Pulmon Dis; 2023; 18():407-418. PubMed ID: 36998390
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations.
    Donohue JF; Worsley S; Zhu CQ; Hardaker L; Church A
    Respir Med; 2015 Jul; 109(7):870-81. PubMed ID: 26006754
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-Effectiveness Analysis of a Once-Daily Single-Inhaler Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) Using the FULFIL Trial: A Spanish Perspective.
    Schroeder M; Benjamin N; Atienza L; Biswas C; Martin A; Whalen JD; Izquierdo Alonso JL; Riesco Miranda JA; Soler-Cataluña JJ; Huerta A; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2020; 15():1621-1632. PubMed ID: 32764908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Healthcare Resource Utilization, Cost and Clinical Outcomes in Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate/Umeclidinium/Vilanterol Based on Exacerbation History.
    Sethi S; Clark B; Bengtson LGS; Buysman EK; Palli S; Sargent A; Shaikh A; Ferguson GT
    Int J Chron Obstruct Pulmon Dis; 2023; 18():625-641. PubMed ID: 37155497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.